Pancreatic Cancer Research

ResearcherCasa Sollievo della SofferenzaActive in the last 2 years

Tiziana Pia Latiano

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9730-5668; OpenAlex author ID A5001689204. Sources: OpenAlex.

Their work

Papers
17 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
26
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: 2 papers · 2019: none · 2020: 1 paper · 2021: 3 papers · 2022: 2 papers · 2023: 3 papers · 2024: 1 paper · 2025: 2 papers · 2026: 2 papers

Papers 17

  1. The Role of Salivary Microbiota in Pancreatic Cancer: From Screening to Tumor Progression and Treatment Response. Last author DOI 10.3390/biomedicines14061407↗
  2. Liquid Biopsy Frontiers in Pancreatic Cancer: Insights from Circulating Cell-Free Nucleic Acids. Co-author DOI 10.3390/cells15100904↗
  3. Comparative Analysis of Fecal Microbiota in Healthy Controls and Pancreatic Cancer Patients: A Focus on Tumor Localization Differences in Pancreatic Head and B… Co-author DOI 10.1002/cam4.71450↗
  4. Could the Microbial Profiling of Normal Pancreatic Tissue from Healthy Organ Donors Contribute to Understanding the Intratumoral Microbiota Signature in Pancre… Co-author DOI 10.3390/microorganisms13020452↗
  5. A powerful machine learning approach to identify interactions of differentially abundant gut microbial subsets in patients with metastatic and non-metastatic p… Co-author DOI 10.1080/19490976.2024.2375483↗
  6. Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary a… Co-author DOI 10.1016/j.esmoop.2022.100777↗
  7. Counteracting gemcitabine+nab-paclitaxel induced dysbiosis in KRAS wild type and KRAS G12D mutated pancreatic cancer in vivo model. Co-author DOI 10.1038/s41420-023-01397-y↗
  8. Evaluation of inherited germline mutations in cancer susceptibility genes among pancreatic cancer patients: a single-center study. Co-author DOI 10.1186/s10020-023-00600-1↗
  9. Butyrate, a postbiotic of intestinal bacteria, affects pancreatic cancer and gemcitabine response in in vitro and in vivo models. Co-author DOI 10.1016/j.biopha.2022.113163↗
  10. Insights into the role of gut and intratumor microbiota in pancreatic ductal adenocarcinoma as new key players in preventive, diagnostic and therapeutic perspe… Co-author DOI 10.1016/j.semcancer.2021.11.007↗
  11. Tuning gut microbiota through a probiotic blend in gemcitabine-treated pancreatic cancer xenografted mice. Co-author DOI 10.1002/ctm2.580↗
  12. Improving Gemcitabine Sensitivity in Pancreatic Cancer Cells by Restoring miRNA-217 Levels. Co-author DOI 10.3390/biom11050639↗
  13. Activity and Safety of NAB-FOLFIRI and NAB-FOLFOX as First-Line Treatment for metastatic Pancreatic Cancer (NabucCO Study). Co-author DOI 10.3390/curroncol28030164↗
  14. High Levels of Prebiotic Resistant Starch in Diet Modulate a Specific Pattern of miRNAs Expression Profile Associated to a Better Overall Survival in Pancreati… Co-author DOI 10.3390/biom11010026↗
  15. Droplet digital PCR quantification of miR-1290 as a circulating biomarker for pancreatic cancer. Co-author DOI 10.1038/s41598-018-34597-z↗
  16. Crosstalk between the Tumor Microenvironment and Immune System in Pancreatic Ductal Adenocarcinoma: Potential Targets for New Therapeutic Approaches. Co-author DOI 10.1155/2018/7530619↗
  17. Combined modality treatments in pancreatic cancer. Co-author DOI 10.1517/14728222.2012.662959↗

Closest collaborators

The 25 strongest of 26 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Francesco Perri · 10 shared papers, 2020–2025 · strength 1.64
  2. Concetta Panebianco · 9 shared papers, 2020–2026 · strength 1.58
  3. Valerio Pazienza · 9 shared papers, 2020–2026 · strength 1.58
  4. Annacandida Villani · 8 shared papers, 2020–2025 · strength 1.25
  5. Evaristo Maiello · 8 shared papers, 2012–2025 · strength 1.05
  6. Francesca Tavano · 4 shared papers, 2018–2026 · strength 0.74
  7. Marco Donatello Delcuratolo · 2 shared papers, 2026 · strength 0.60
  8. Andrea Fontana · 2 shared papers, 2023–2024 · strength 0.35
  9. Maria Latiano · 1 shared paper, 2026 · strength 0.27
  10. Nadia Trivieri · 2 shared papers, 2020–2021 · strength 0.25
  11. Fabio F. di Mola · 1 shared paper, 2025 · strength 0.22
  12. Tommaso Mazza · 1 shared paper, 2025 · strength 0.22
  13. Guido Giordano · 2 shared papers, 2018–2021 · strength 0.19
  14. Vanja Vaccaro · 1 shared paper, 2021 · strength 0.11
  15. Caterina Vivaldi · 1 shared paper, 2021 · strength 0.11
  16. Elisa Giommoni · 1 shared paper, 2021 · strength 0.11
  17. Francesco Di Costanzo · 1 shared paper, 2021 · strength 0.11
  18. Giampaolo Tortora · 1 shared paper, 2021 · strength 0.11
  19. Lorenzo Antonuzzo · 1 shared paper, 2021 · strength 0.11
  20. Serena Pillozzi · 1 shared paper, 2021 · strength 0.11
  21. Massimo Pancione · 1 shared paper, 2018 · strength 0.08
  22. Angelo Andriulli · 1 shared paper, 2018 · strength 0.08
  23. Paola Parente · 1 shared paper, 2018 · strength 0.08
  24. Lucia Lombardi · 1 shared paper, 2012 · strength 0.03
  25. Pierluigi Di Sebastiano · 1 shared paper, 2012 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.